Mizuho Securities Maintains Their Buy Rating on CytomX Therapeutics (CTMX)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on CytomX Therapeutics (CTMXResearch Report) today and set a price target of $16.00. The company’s shares closed last Friday at $6.76.

According to TipRanks.com, Goldstein is a 3-star analyst with an average return of 1.6% and a 38.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

CytomX Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.50.

See today’s analyst top recommended stocks >>

Based on CytomX Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $16.61 million and GAAP net loss of $15.68 million. In comparison, last year the company earned revenue of $9.01 million and had a GAAP net loss of $28.96 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.